Target ALS is a New York-based medical research foundation dedicated to finding effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Founded in 2013, Target ALS has revolutionized ALS research through its innovative Innovation Ecosystem model, fostering collaboration between academia and the pharmaceutical biotech industry. Their approach has led to groundbreaking breakthroughs in ALS research, including potentially viable treatments for the disease.
Target ALS addresses the barriers that have hindered progress in ALS research, such as limited funding opportunities, siloed research, lack of scientific resources, and bias in funding decisions. By providing financial support and research tools, Target ALS empowers researchers to advance their work effectively. Their current priorities include the discovery of biomarkers for early diagnosis, the development of new drugs, and the acceleration of clinical trials. Join Target ALS in their mission to discover the first viable treatments for ALS and change the future for ALS patients.
Generated from the website
